Related Experiment Video
Updated: Nov 19, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
[Developments in Immunotherapy for Advanced Non-small Cell Lung Cancer]
Haoyang Li1, Jinghui Wang1,2
1Department of Medical Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
Immunotherapy, in particular immune checkpoint inhibitors, has significantly improved the survival outcomes of advanced lung cancer patients and changed the treatment mode of lung cancer. In this article, we reviewed the mechanism of immunotherapy, the clinical trials that changed treatment guidelines, the important biomarkers, immune-related adverse events, and descripted the future of immunotherapy of advanced non-small cell lung cancer. .
Immunotherapy, in particular immune checkpoint inhibitors, has significantly improved the survival outcomes of advanced lung cancer patients and changed the treatment mode of lung cancer. In this article, we reviewed the mechanism of immunotherapy, the clinical trials that changed treatment guidelines, the important biomarkers, immune-related adverse events, and descripted the future of immunotherapy of advanced non-small cell lung cancer. .
More Related Videos
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against...